IG
BMRN icon

ING Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

ING Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-210,000
Closed -$18.3M – 548
2024
Q1 		$18.3M Hold
210,000
– – 0.13% 142
2023
Q4 		$20.2M Buy
+210,000
New +$18.6M 0.16% 128
2019
Q2 		– Sell
-5,814
Closed -$516K – 760
2019
Q1 		$516K Sell
5,814
-3,077
-35% -$285K 0.01% 444
2018
Q4 		$757K Sell
8,891
-3,649
-29% -$347K 0.02% 381
2018
Q3 		$1.22M Buy
12,540
+8,805
+236% +$879K 0.02% 332
2018
Q2 		$352K Buy
3,735
+100
+3% +$8.76K 0.01% 575
2018
Q1 		$295K Sell
3,635
-1,087
-23% -$93.3K 0.01% 621
2017
Q4 		$421K Sell
4,722
-728
-13% -$63.3K 0.01% 546
2017
Q3 		$507K Buy
+5,450
New +$482K 0.01% 469
2016
Q3 		– Sell
-737,335
Closed -$57.4M – 573
2016
Q2 		$57.4M Buy
+737,335
New +$62.7M 0.77% 28
2016
Q1 		– Sell
-25,700
Closed -$2.69M – 552
2015
Q4 		$2.69M Buy
25,700
+10,240
+66% +$1.07M 0.02% 385
2015
Q3 		$1.63M Buy
15,460
+12,983
+524% +$1.73M 0.01% 392
2015
Q2 		$339K Sell
2,477
-254,061
-99% -$31.5M ﹤0.01% 585
2015
Q1 		$32M Buy
+256,538
New +$27.2M 0.16% 144
2013
Q4 		– Sell
-186,953
Closed -$13.5M – 695
2013
Q3 		$13.5M Buy
+186,953
New +$12.4M 0.07% 256

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

ING Group's BMRN Position: Q2 2024 in Review

ING Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 210,000 shares — an estimated $18.3M sold.

ING Group first reported a position in BMRN in Q3 2013 and held it in 15 quarters. The position peaked at $57.4M in Q2 2016. 560 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • ING Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • ING Group sold 210,000 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $18.3M.
  • ING Group first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 15 quarters.
  • ING Group's BioMarin Pharmaceuticals position peaked at $57.4M in Q2 2016.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on ING Group's 13F filing for Q2 2024, filed 13 Aug 2024.